Protocol Ledger

NCT06631170 · Phase III · COMPLETED

Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis

Interventional Phase III clinical trial protocol NCT06631170 sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-21 Enrollment: 354 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06631170
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)354 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06631170
Protocol FieldVerified Registry Value
NCT IdentifierNCT06631170
Consolidated Lead SponsorHangzhou Zhongmei Huadong Pharmaceutical Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment354 participants (ACTUAL)
Registered Start Date2024-11-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06631170
Hospital Research SiteLocationSite Profile
Beijing Tsinghua Changgung HospitalBeijing, ChinaOpen Hospital Dossier ->
Fujian Medical University Union HospitalFuzhou, ChinaOpen Hospital Dossier ->
Dongguan People's HospitalDongguan, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI